TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28602417
Drug: Commonly used
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly used radiation therapy (40 Gy in 15 fractions, arm 2)
Study: 26261149
Drug: Removal of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removal of dental materials in patients with oral lichenoid lesions (13 patients consented to removal)
Study: 26261149
Drug: Patch tests
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch tests for dental restoration materials
Study: 11054013
Drug: Topical furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical furosemide after surgical treatment
Study: 11054013
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment after surgical treatment (Control)
Study: 9296823
Drug: Electrocauthery plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocauthery plus immunotherapy
Study: 26703894
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (100% oxygen at 2.4 ATA)
Study: 8878069
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.25‐0.5 U/kg/week)
Study: 1959783
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin in combination with epirubicin
Study: 1959783
Drug: Weekly cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly cisplatin in combination with etoposide
Study: 6318351
Drug: Bi‐Profenid 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bi‐Profenid 150 mg (two daily doses of 150 mg)
Study: 6318351
Drug: Indomethacin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (two daily doses of 50 mg)
Study: 29429593
Drug: BDP/FF/G (beclometasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDP/FF/G (beclometasone dipropionate, formoterol fumarate, and glycopyrronium) 87 μg/5 μg/9 μg, two inhalations per day
Study: 29429593
Drug: IND/GLY (indacaterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND/GLY (indacaterol plus glycopyrronium) 85 μg/43 μg, one inhalation per day
Study: 27614902
Drug: State EITC
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: State EITC supplements
Study: 27614902
Drug: State EITC
Normalized name: CLOZAPINE (GOLDEN STATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: State EITC supplements for a family of three
Study: 18602526
Drug: Fosinopril treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril treatment for 3 months
Study: 15809548
Drug: Inhaled bronchodilator
Normalized name: Bronchodil
DrugBank: Reproterol (DB12846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled bronchodilator (albuterol/ipratropium bromide solution)
Study: 10965009
Drug: Bolus intrathecal
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intrathecal injections of 50 microg of baclofen
Study: 10965009
Drug: Bolus intrathecal
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intrathecal injections of 75 microg of baclofen
Study: 10965009
Drug: Continuous intrathecal
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intrathecal administration of baclofen via subcutaneous pump
Study: 8791041
Drug: Flunitrazepam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunitrazepam (1 mg intravenous)
Study: 1611810
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam intravenously in 15 minutes
Study: 1611810
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg alpha-hydroxymidazolam intravenously in 15 minutes
Study: 1611810
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg midazolam orally
Study: 6231156
Drug: Intravenous saralasin
Normalized name: saralasin
DrugBank: Saralasin (DB06763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous saralasin (0.5, 1 and 5 micrograms min‐1 kg‐1) in tetraplegic patients
Study: 6231156
Drug: Intravenous saralasin
Normalized name: saralasin
DrugBank: Saralasin (DB06763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous saralasin (5 micrograms kg‐1 min‐1) in tetraplegic patients after alpha‐adrenoceptor blockade with thymoxamine (1 mg kg‐1 h‐1)
Study: 6231156
Drug: Intravenous saralasin
Normalized name: saralasin
DrugBank: Saralasin (DB06763)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous saralasin in both groups (tetraplegic patients and normal subjects)
Study: 29623135
Drug: High-Flow Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Oxygen Therapy (HFO)
Study: 29623135
Drug: Mask Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mask Oxygen Therapy
Study: 27015606
Drug: Immediate triple
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate triple therapy (IT)
Study: 27015606
Drug: Step-up triple
Normalized name: STEP 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Step-up triple therapy (ST)
Study: 18586124
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (supervised, group program, 6 exercises using weight machines, performed twice a week for 10 weeks, 2-3 sets of 10-12 repetitions until fatigue)
Study: 9661603
Drug: pamidronate (APD)
DrugBank: Pamidronic acid (DB00282)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pamidronate (APD) 30 mg i.v. every 3 months for 2 yr
Study: 2699997
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 grams added to dialysis bath for three months) during acetate hemodialysis
Study: 2699997
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 grams added to dialysis bath for three months) during bicarbonate hemodialysis
Study: 832179
Drug: Intramuscular atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular atropine as the only premedication
Study: 832179
Drug: Intravenous atropine
Normalized name: Atropine
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous atropine at the time of induction of anaesthesia
Study: 29534997
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Study: 29534997
Drug: 10 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 months of monthly degarelix (first dose 240 mg, subsequent doses 80 mg per month)
Study: 29534997
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of monthly degarelix
Study: 29534997
Drug: 10 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 months of monthly degarelix
Study: 26728893
Drug: AZD2327 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD2327 (3 mg BID)
Study: 25109239
Drug: Zonisamide (200-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zonisamide (200-500 mg/day)
Study: 25109239
Drug: Carbamazepine (400-1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine (400-1,200 mg/day)
Study: 29705869
Drug: Suvorexant 10
Normalized name: suvorexant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 10 mg
Study: 31992394
Drug: Suvorexant 20
Normalized name: suvorexant 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant 20 mg
Study: 26039969
Drug: Suvorexant 40
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 40 mg
Study: 29705869
Drug: Suvorexant 80
Normalized name: Suvorexant
DrugBank: Suvorexant (DB09034)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Suvorexant 80 mg
Study: 23197752
Drug: Suvorexant (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suvorexant (all doses combined)
Study: 18557167
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate infusion (30 mg/kg over 10 minutes, then 10 mg/kg/hr throughout surgery)
Study: 15784063
Drug: Nefazodone (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (300 mg/day)
Study: 20186295
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg(‐1)
Study: 12641685
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg(‐1) + Midazolam 0.1 mg.kg(‐1)
Study: 12641685
Drug: Ketamine 2
Normalized name: esketamine 28 mg nasal spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 2 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Study: 12641685
Drug: Ketamine 1
Normalized name: ketamine 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine 1 mg.kg(‐1) + Midazolam 0.2 mg.kg(‐1)
Study: 10594542
Drug: Intravenous prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous prednisolone 80 mg
Study: 2072220
Drug: Penicillin therapy
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penicillin therapy only
Study: 6134298
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam (20 mg)
Study: 30447052
Drug: Resistin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistin concentration ≥ 11.4 ng/mL
Study: 30447052
Drug: Resistin concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resistin concentration above 11 ng/mL
Study: 30308428
Drug: LEV-ER (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV-ER (extended-release levetiracetam)
Study: 30308428
Drug: LEV-IR (immediate-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEV-IR (immediate-release levetiracetam)
Study: 27468543
Drug: A &
Normalized name: A & D OINT
Approvals — FDA: no, EMA: no, PMDA: no
Description: A & As particle 15.2 g/day
Study: 16534240
Drug: 100 microg
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 microg intravenously administered CRH
Study: 16534240
Drug: 12 mg
Normalized name: pectin 12 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 mg naloxone
Study: 9635603
Drug: Indomethacin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (50 mg three times a day)
Study: 1656040
Drug: Lisinopril (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (10-20 mg once daily)
Study: 12011663
Drug: Valsartan (80-160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (80-160 mg once daily)
Study: 10850318
Drug: 500 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/m2 amifostine intravenously prior to HD-RIT
Study: 10850318
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg amifostine prior to HD-RIT in rabbits
Study: 1936073
Drug: Rokitamycin 200
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 200 mg
Study: 1936073
Drug: Rokitamycin 300
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 300 mg
Study: 1936073
Drug: Rokitamycin 400
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 400 mg
Study: 1936073
Drug: Rokitamycin 600
Normalized name: rokitamycin
DrugBank: Rokitamycin (DB13409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rokitamycin 600 mg
Study: 29525393
Drug: Intervention (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention (active vitamin D sterol dose increase)
Study: 27508314
Drug: Comprehensive Reminder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Reminder System (health belief education, calendar handbook, weekly automated SMS, four telephone follow-ups)
Study: 24886036
Drug: Lecithinized superoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithinized superoxide dismutase (40 or 80 mg)
Study: 24886036
Drug: Lecithinized superoxide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithinized superoxide dismutase (80 mg)
Study: 20563466
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA alone (Group A)
Study: 20563466
Drug: Morphine PCA
Normalized name: lauryl PCA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine PCA plus continuous infusion (Group B)
Study: 18520951
Drug: Fosinopril/hydrochlorothiazide combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosinopril/hydrochlorothiazide combination (10/12.5 mg titrated up to 20/12.5 mg)
Study: 18520951
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg titrated up to 10 mg)
Study: 6373155
Drug: Indapamide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indapamide (2.5 mg)
Study: 15939732
Drug: Intravenous aminophylline
Normalized name: Aminophylline
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous aminophylline 0.5 mg/kg/hour after an appropriate loading dose
Study: 12463729
Drug: Galantamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine and risperidone administered together
Study: 12463729
Drug: Galantamine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine and risperidone administered alone
Study: 7851589
Drug: 16 mg
Normalized name: escin 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 mg oral 6-alpha-methylprednisolone for four evenings starting the evening of retrieval or the evening before thawing cryopreserved embryos, plus 250 mg oral tetracycline four times per day for 4 days.
Study: 7851589
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered in an identical fashion, plus 250 mg oral tetracycline four times per day for 4 days.
Study: 6127319
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg/kg body weight)
Study: 6127319
Drug: Tobramycin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tobramycin (1 mg/kg body weight) + Cefotaxime (2 g)
Study: 10150322
Drug: Cefotaxime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (2 g)
Study: 23351827
Drug: LABR‐312 (low-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABR‐312 (low-dose)
Study: 23351827
Drug: LABR‐312 (high-dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABR‐312 (high-dose)
Study: 11703951
Drug: Eptifibatide 135
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 135 microg/kg bolus followed by 0.75 microg/kg/min infusion
Study: 11703951
Drug: Eptifibatide 180
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 180 microg/kg bolus followed by 2.0 microg/kg/min infusion
Study: 11703951
Drug: Eptifibatide 250
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eptifibatide 250 microg/kg bolus followed by 3.0 microg/kg/min infusion
Study: 9141536
Drug: [Nle27]GHRH-(1-29)-NH2 at
Approvals — FDA: no, EMA: no, PMDA: no
Description: [Nle27]GHRH-(1-29)-NH2 at a dose of 10 microg/kg, administered nightly for 16 weeks after 4 weeks of placebo.
Study: 7867114
Drug: Nicardipine hydrochloride,
Normalized name: NiCARdipine Hydrochloride, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine hydrochloride, 0.03 mg.kg‐1 iv
Study: 7867114
Drug: Verapamil hydrochloride,
Normalized name: Verapamil Hydrochloride, 80 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil hydrochloride, 0.1 mg.kg‐1 iv
Study: 2765348
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine 15 mg plus clonidine 1 ml (150 micrograms)
Study: 2765348
Drug: 0.5% isobaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% isobaric bupivacaine 15 mg plus isotonic saline 1 ml
Study: 49560
Drug: Self-administered nitrous
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered nitrous oxide 50%/oxygen 50% ('Entonox' analgesic apparatus)
Study: 23222003
Drug: Intracoronary nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary nitroglycerin (250-μg)
Study: 23222003
Drug: Intracoronary diltiazem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary diltiazem (5-mg)
Study: 11138763
Drug: Listeners making
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Listeners making specific responses (e.g., wincing, exclaiming)
Study: 11138763
Drug: Listeners making
Normalized name: MASK
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Listeners making generic responses (e.g., nodding, vocalizations)
Study: 19803399
Drug: IV rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV rt‐PA therapy at a dose of 0.9 mg/kg
Study: 19803399
Drug: IV rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV rt‐PA therapy at a dose of 0.6 mg/kg
Study: 19803399
Drug: IV rt‐PA
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV rt‐PA administered 3‐4.5 hours after symptom onset
Study: 19803399
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of reperfusion therapies (IV rt‐PA and sonothrombolysis, neuroprotective agents, or antiplatelet agents)
Study: 19803399
Drug: Higher dose
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher dose of alteplase, combined IV/IA thrombolysis, or mechanical thrombectomy
Study: 17488248
Drug: Intramuscular octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular octreotide 20 mg (group A) q 4 wk for 3 months
Study: 14961057
Drug: Clomipramine 25
Normalized name: clomiPRAMINE 25 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 25 mg as needed
Study: 14961057
Drug: Clomipramine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clomipramine 20 or 30 mg daily
Study: 12516788
Drug: 75 grams
Normalized name: vancomycin
DrugBank: Vancomycin (DB00512)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 grams of superactivated charcoal (SAC) administered orally in a slurry 3 hours after acetaminophen dose
Study: 9862941
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and antibiotics (20 mg omeprazole orally twice daily, 500 mg amoxicillin three times daily, 400 mg metronidazole three times daily for 2 weeks)
Study: 9862941
Drug: Omeprazole and
Normalized name: Omeprazole and Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole and antibiotics
Study: 9818646
Drug: Non-depleting humanized
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-depleting humanized monoclonal antibody to CD4 (ORTHOCLONE OKTcdr4a) at a dosage of +/-450 mg per week for 2 treatment cycles, followed by a crossover to placebo for the third cycle.
Study: 2695726
Drug: 3 x
Normalized name: Xenon (133 xe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 x 1 g claforan given during a period of 24 h (regimen I)
Study: 2695726
Drug: 1 x
Normalized name: Black Cohosh 1 X Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 x 1 g claforan given at the time of incision (regimen II)
Study: 2695726
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cefapirin + gentamicin given in divided doses for 5 days (regimen III)
Study: 719463
Drug: Intravenous load
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous load of 11 of Hartmann's solution
Study: 719463
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no intravenous load)
Study: 28533045
Drug: Animal-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Animal-assisted therapy sessions
Study: 25593483
Drug: RetroView™ colonoscope
Approvals — FDA: no, EMA: no, PMDA: no
Description: RetroView™ colonoscope in combination withdrawal (standard + retroflexed)
Study: 7909525
Drug: N-acetyl-cysteine (NAC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl-cysteine (NAC) treatment
Study: 11388971
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment need
Study: 7685687
Drug: Diclofenac/misoprostol combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac/misoprostol combination dosage form
Study: 7685687
Drug: Diclofenac (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (single and multiple doses) in elderly volunteers
Study: 3718599
Drug: Acemetacin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (90 mg, single administration)
Study: 3718599
Drug: Acemetacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acemetacin (2 retard capsules/d for 8 d, multiple administration)
Study: 24756483
Drug: 2g omega-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g omega-3 PUFA daily, initiated 5 days before surgery
Study: 16555574
Drug: Valsartan (40‐80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (40‐80 mg)
Study: 31811715
Drug: Ticagrelor 60
Normalized name: ticagrelor 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 60 mg or 90 mg plus aspirin
Study: 31662524
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day solifenacin
Study: 23490379
Drug: albIFN 900/1200/1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: albIFN 900/1200/1500 μg q4wk
Study: 23490379
Drug: Peg‐IFNα‐2a 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peg‐IFNα‐2a 180 μg qwk
Study: 23490379
Drug: oral ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral ribavirin 800 mg/d
Study: 21289240
Drug: Salsalate (4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salsalate (4000 mg Disalsid)
Study: 19729945
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (BUD) for 4 weeks
Study: 19729945
Drug: No budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No budesonide treatment (Control)